argenex SE (NASDAQ:ARGX) Receives $1,017.78 Consensus Price Target from Brokerages

Shares of argenex SE (NASDAQ:ARGX) have been assigned an average recommendation of “Moderate Buy” from the twenty-four research firms that are currently covering the firm, Marketbeat Ratings reports. Four analysts have rated the stock with a hold recommendation, eighteen have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $1,019.50.

Several research firms have issued reports on ARGX. Zacks Research upgraded shares of argenex from a “strong sell” rating to a “hold” rating in a research report on Friday, February 20th. Wedbush reaffirmed an “outperform” rating and set a $1,000.00 price objective on shares of argenex in a research note on Monday, March 9th. Glj Research raised shares of argenex to a “strong-buy” rating in a research note on Friday, April 3rd. Robert W. Baird upped their price objective on shares of argenex from $858.00 to $867.00 and gave the company a “neutral” rating in a research note on Friday, February 27th. Finally, Oppenheimer lowered their price objective on shares of argenex from $1,060.00 to $1,014.00 and set an “outperform” rating for the company in a research note on Thursday, April 2nd.

Hedge Funds Weigh In On argenex

Several hedge funds and other institutional investors have recently modified their holdings of the company. AQR Capital Management LLC raised its stake in argenex by 32.1% in the first quarter. AQR Capital Management LLC now owns 502 shares of the company’s stock worth $297,000 after buying an additional 122 shares in the last quarter. NewEdge Advisors LLC raised its stake in argenex by 5,962.5% in the first quarter. NewEdge Advisors LLC now owns 1,455 shares of the company’s stock worth $862,000 after buying an additional 1,431 shares in the last quarter. Focus Partners Wealth raised its stake in argenex by 22.3% in the first quarter. Focus Partners Wealth now owns 400 shares of the company’s stock worth $237,000 after buying an additional 73 shares in the last quarter. Geneos Wealth Management Inc. raised its stake in argenex by 550.0% in the first quarter. Geneos Wealth Management Inc. now owns 117 shares of the company’s stock worth $69,000 after buying an additional 99 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. raised its stake in argenex by 60.2% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 133 shares of the company’s stock worth $73,000 after buying an additional 50 shares in the last quarter. 60.32% of the stock is owned by institutional investors.

argenex Stock Up 1.4%

NASDAQ ARGX opened at $813.14 on Monday. The company has a 50-day simple moving average of $787.72 and a two-hundred day simple moving average of $813.34. argenex has a 12-month low of $510.05 and a 12-month high of $934.62. The firm has a market cap of $50.57 billion, a price-to-earnings ratio of 36.20, a PEG ratio of 1.27 and a beta of 0.47.

argenex (NASDAQ:ARGX) last posted its quarterly earnings results on Tuesday, March 31st. The company reported $5.52 earnings per share (EPS) for the quarter. argenex had a net margin of 31.31% and a return on equity of 33.28%. The business had revenue of $1.31 billion during the quarter. Equities analysts expect that argenex will post 25.34 earnings per share for the current fiscal year.

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.